Skip to main content

Bradbury Daniel's Form 4 filing

Castle Biosciences Inc (CSTL) · filed May 8, 2023

Accession no.
0001447362-23-000071
Filed
May 8, 2023
Trade date
May 4-5, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 12 non-derivative transactions. Open-market sales total $540.8K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bradbury DanielCIK 0001236397Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 4, 2023Common StockSSaleDisposed−3,400$21.29F2−$72,386151,139Indirect
May 4, 2023Common StockSSaleDisposed−1,134$21.29F2−$24,142.8681,646Indirect
May 4, 2023Common StockSSaleDisposed−1,133$21.29F2−$24,121.5781,672Indirect
May 4, 2023Common StockSSaleDisposed−7,185$21.88F6−$157,207.8143,954Indirect
May 4, 2023Common StockSSaleDisposed−2,395$21.88F6−$52,402.679,251Indirect
May 4, 2023Common StockSSaleDisposed−2,396$21.88F6−$52,424.4879,276Indirect
May 5, 2023Common StockSSaleDisposed−2,039$21.12F7−$43,063.68141,915Indirect
May 5, 2023Common StockSSaleDisposed−679$21.12F7−$14,340.4878,572Indirect
May 5, 2023Common StockSSaleDisposed−680$21.12F7−$14,361.678,596Indirect
May 5, 2023Common StockSSaleDisposed−2,376$21.80F8−$51,796.8139,539Indirect
May 5, 2023Common StockSSaleDisposed−792$21.80F8−$17,265.677,780Indirect
May 5, 2023Common StockSSaleDisposed−791$21.80F8−$17,243.877,805Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $20.640 to $21.635, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $21.640 to $22.310, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $20.570 to $21.565, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

F8

This transaction was executed in multiple trades at prices ranging from $21.570 to $22.145, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)